Etirinotecan pegol (trade name Onzeald) is a drug developed by Nektar Therapeutics for the treatment of certain kinds of breast cancer with brain metastases. The European Medicines Agency refused to grant it a marketing authorisation in 2017.
Attributes | Values |
---|---|
rdf:type | |
rdfs:label |
|
rdfs:comment |
|
foaf:depiction | |
dcterms:subject | |
Wikipage page ID |
|
Wikipage revision ID |
|
Link from a Wikipage to another Wikipage | |
sameAs | |
dbp:wikiPageUsesTemplate | |
thumbnail | |
ATC suffix |
|
ATC prefix |
|
CAS number |
|
DrugBank |
|
elimination half-life |
|
excretion |
|
KEGG |
|
molecular weight |
|
routes of administration | |
synonyms |
|
tradename |
|
UNII |
|
has abstract |
|
Chemical Formula |
|
metabolites |
|
protein bound |
|
chemical formula |
|
prov:wasDerivedFrom | |
page length (characters) of wiki page |
|
alternative name |
|
CAS number |
|
DrugBank |
|
FDA UNII code |
|
KEGG |
|
foaf:isPrimaryTopicOf | |
is Link from a Wikipage to another Wikipage of | |
is Wikipage redirect of | |
is foaf:primaryTopic of |